Gallant Therapeutics to Commence JEDI Study of First Allogeneic Stem Cell Therapy for Feline Chronic Gingivostomatitis (FCGS) in Cats
Shots:
- Gallant will commence the JEDI study to assess the safety and efficacy of allogeneic stem cell therapy in cats with refractory FCGS, aiming to secure the US FDA conditional approval. Product’s ready-to-use formulation will be crucial for its success as a pioneering treatment in veterinary medicine
- The study is based on successful pilot studies showing mesenchymal stem cell (MSC) efficacy in improving clinical status and lesion scores in refractory FCGS cats
- The company is actively recruiting cats under an FDA-approved protocol at veterinary dental specialist sites in the US
Ref: Globenewswire | Image: Gallant Therapeutics
Related News:- Jaguar Animal Health Reports an Availability of Canalevia-CA1 on Chewy for Chemotherapy-Induced Diarrhea in Dogs
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Kritika is a content writer at PharmaShots. She is interested in covering recent innovations from the pharma & MedTech industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
